Corcept Therapeutics (NASDAQ:CORT) Releases Earnings Results

Corcept Therapeutics (NASDAQ:CORT) issued its quarterly earnings data on Tuesday. The biotechnology company reported $1.01 EPS for the quarter, beating the consensus estimate of $0.84 by $0.17, FiscalAI reports. The firm had revenue of $340.47 million during the quarter, compared to the consensus estimate of $339.12 million. Corcept Therapeutics had a net margin of 16.53% and a return on equity of 24.00%. The company’s quarterly revenue was up 64.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.16 earnings per share.

Here are the key takeaways from Corcept Therapeutics’ conference call:

• Third-quarter revenue rose 64% year over year to $340.5 million, while net income increased to $126.8 million and cash and investments reached $662 million. Management reiterated 2026 revenue guidance of $1.1 billion to $1.2 billion.
• Lifyorli revenue climbed 92% sequentially to $91.4 million, with more than 2,300 patients treated since launch and increasing repeat prescribing. Management believes the drug can become the market-share leader in platinum-resistant ovarian cancer and generate more than $1 billion in annual revenue.
• Corcept expects broader screening recommendations for hypercortisolism to expand its endocrinology market, forecasting at least $2 billion in annual Cushing’s syndrome revenue by the end of the decade, potentially reaching $3 billion to $5 billion in 2030 with relacorilant.
• The FDA is reviewing relacorilant’s resubmitted Cushing’s syndrome application, with a December 17 PDUFA date; management provided no additional regulatory detail. The company also plans additional studies in oncology, MASH, and ALS, with several results expected by the end of next year.

Corcept Therapeutics Trading Down 4.7%

NASDAQ:CORT traded down $3.69 during midday trading on Thursday, reaching $75.53. The company had a trading volume of 256,389 shares, compared to its average volume of 1,469,850. The stock’s fifty day simple moving average is $109.43 and its 200-day simple moving average is $75.28. The firm has a market capitalization of $8.16 billion, a price-to-earnings ratio of 59.42 and a beta of 0.54. Corcept Therapeutics has a 12-month low of $28.66 and a 12-month high of $126.38.

Insider Transactions at Corcept Therapeutics

In other Corcept Therapeutics news, insider Roberto Vieira sold 8,333 shares of the firm’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $80.89, for a total transaction of $674,056.37. Following the sale, the insider directly owned 3,946 shares of the company’s stock, valued at $319,191.94. This trade represents a 67.86% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director James N. Wilson sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $114.81, for a total transaction of $1,148,100.00. Following the completion of the transaction, the director directly owned 1,054,543 shares of the company’s stock, valued at approximately $121,072,081.83. This represents a 0.94% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 382,536 shares of company stock worth $43,406,554 over the last quarter. Insiders own 20.70% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently commented on CORT shares. Zacks Research cut Corcept Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 27th. HC Wainwright restated a “buy” rating and set a $165.00 price target on shares of Corcept Therapeutics in a report on Friday, September 18th. Weiss Ratings raised shares of Corcept Therapeutics from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, September 24th. Truist Financial started coverage on shares of Corcept Therapeutics in a research note on Tuesday, August 18th. They set a “buy” rating and a $164.00 price objective for the company. Finally, Canaccord Genuity Group upped their target price on shares of Corcept Therapeutics from $135.00 to $150.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. Five analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $139.50.

Corcept Therapeutics News Roundup

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Q3 revenue increased 64% year over year to $340.5 million, slightly above estimates, while EPS of $1.01 beat the $0.84 consensus. Higher Korlym sales and Lifyorli uptake contributed to growth. Article: CORT’s Q3 earnings beat
• Positive Sentiment: Piper Sandler reaffirmed its “overweight” rating and raised its price target to $173 from $165. HC Wainwright also kept a “buy” rating and a $165 target, although it lowered its Q1 2027 EPS estimate.
• Neutral Sentiment: Corcept is awaiting a December 17 FDA decision on relacorilant and has outlined a long-term opportunity of $3 billion to $5 billion in Cushing’s syndrome revenue by 2030. Both remain dependent on regulatory and commercial execution. Article: Corcept’s relacorilant decision and revenue target
• Negative Sentiment: The stock’s decline following the earnings release suggests investors were more concerned about company guidance than the quarterly beat. Guidance-related concerns have outweighed the strong reported growth. Article: Corcept falls on guidance despite earnings beat
• Negative Sentiment: Several insiders sold substantial holdings: Roberto Vieira sold 8,333 shares, while Sean Maduck sold shares in two transactions totaling 25,000. Such sales can weigh on sentiment, though they do not necessarily indicate a change in company outlook. Article: Corcept insider stock sales
• Negative Sentiment: A newly disclosed risk highlights potential operational and financial exposure from reliance on AI tools and vendor systems, including cybersecurity and data-security threats. The report does not describe a specific breach. Article: Cyber and data-security risks

About Corcept Therapeutics

Corcept Therapeutics Incorporated (NASDAQ:CORT) is a commercial-stage biopharmaceutical company focused on developing medicines that selectively modulate the glucocorticoid receptor. The company’s research is based on the role of excess cortisol in metabolic, psychiatric, oncologic and other serious medical conditions.

Corcept’s primary marketed product is Korlym (mifepristone), an oral glucocorticoid receptor antagonist approved in the United States to control hyperglycemia secondary to endogenous Cushing’s syndrome in adults with type 2 diabetes or glucose intolerance who are not candidates for surgery or have not responded adequately to surgery.